CureAlz Taps Pharma Insiders to Guide Its Independent Research Engine

WELLESLEY HILLS, Mass. – September 09, 2026

In a move that signals a significant strategic pivot in the nonprofit war on Alzheimer's, Cure Alzheimer's Fund (CureAlz) has appointed four titans of pharmaceutical drug development to its Scientific Advisory Board (SAB). The announcement is a study in contrasts: an organization fiercely proud of its independence from pharmaceutical funding is now entrusting its scientific direction to veterans from the very industry it keeps at arm's length. This isn't a contradiction; it's a calculated strategy to bridge the chasm between promising lab research and effective patient therapies.

The new appointments—Drs. Michelle Arkin, Ronald B. DeMattos, Donna M. Huryn, and Kalpana Merchant—represent a formidable infusion of translational expertise. They bring decades of experience from the front lines of companies like Eli Lilly, Hoffmann-La Roche, and Wyeth, transforming abstract scientific concepts into clinically tested drugs. By embedding this industry DNA into its core, CureAlz is re-engineering its approach, aiming to become a more effective catalyst in the high-stakes race for a cure.

A Strategic Infusion of Drug Development DNA

The collective resume of the new board members reads like a blueprint for modern drug discovery. Dr. Ronald B. DeMattos is perhaps the most prominent name, having recently retired as Senior Vice President at Eli Lilly, where he was a key leader in the development of donanemab (Kisunla™), one of the first FDA-cleared antibodies proven to clear amyloid plaques and slow cognitive decline in early Alzheimer's patients. His involvement provides CureAlz with direct insight into the arduous, multi-billion-dollar process of bringing a blockbuster neurodegenerative therapy from concept to market.

Joining him is Dr. Michelle Arkin, a professor at UCSF and co-founder of four therapeutics startups, whose work focuses on a critical frontier in drug discovery: targeting proteins once considered "undruggable." Her expertise in small-molecule chemistry offers a vital alternative and complement to the large-molecule antibody therapies that have recently dominated headlines. This focus is crucial for developing next-generation treatments that could potentially be delivered as pills rather than infusions, broadening patient access and ease of use.

Dr. Donna M. Huryn, a professor at the University of Pennsylvania and a fellow of the American Chemical Society's Medicinal Chemistry Hall of Fame, brings a career forged at pharmaceutical giants Hoffmann-La Roche and Wyeth. Her work designing small-molecule drug candidates for neurodegenerative diseases adds another layer of deep chemical and therapeutic expertise. Similarly, Dr. Kalpana Merchant, a former Chief Scientific Officer at Eli Lilly and founder of a translational neuroscience consultancy, offers over 30 years of experience guiding drug development strategies. Her work advising organizations like the Michael J. Fox Foundation and the NIH underscores her role as a bridge between foundational science and clinical application.

"The addition of Drs. Arkin, DeMattos, Huryn, and Merchant further strengthens an already-exceptional Scientific Advisory Board and reinforces our commitment to identifying and funding the highest-impact Alzheimer's research," said Meg Smith, CEO of Cure Alzheimer's Fund. Her statement highlights the core of this strategy: not just funding science, but funding the right science with the highest probability of clinical success.

A Model of Independent Innovation

This strategic recruitment drive is made all the more compelling by CureAlz's unique operational model. The organization famously refuses funding from pharmaceutical or biotech companies, a policy designed to eliminate any potential for commercial interests to color its research agenda. This independence is underwritten by its Board of Directors and other sustaining partners, who cover all administrative overhead. The result is a promise to donors that 100% of their contributions go directly to research—a promise validated by 14 consecutive years of perfect scores from the watchdog group Charity Navigator.

By pairing this financial independence with an advisory board rich in industry acumen, CureAlz is attempting to create a best-of-both-worlds scenario. It can fund high-risk, paradigm-shifting research that a publicly-traded pharmaceutical company might deem too speculative, while simultaneously vetting those projects with the pragmatic, milestone-driven mindset of seasoned drug developers. These new advisors understand the myriad reasons a promising compound can fail on its long journey to FDA approval and can help steer the fund's investments toward projects with the most robust scientific and developmental foundations.

This hybrid model represents a sophisticated evolution for nonprofit medical research. It acknowledges that while academic freedom is paramount for discovery, the specialized knowledge required to navigate clinical trials, regulatory hurdles, and manufacturing challenges resides primarily within the private sector. Instead of accepting industry cash, CureAlz is importing its most valuable asset: its human capital.

Navigating the Post-Amyloid Landscape

The timing of these appointments is critical. The Alzheimer's treatment landscape has been fundamentally altered by the recent full FDA approvals of lecanemab (Leqembi™) and donanemab (Kisunla™). These anti-amyloid antibody therapies, while historic, are not a panacea. They offer modest benefits in slowing cognitive decline for a specific subset of patients in the disease's early stages and come with risks like amyloid-related imaging abnormalities (ARIA). Their arrival has closed one chapter of Alzheimer's research while simultaneously highlighting the urgent need to open several new ones.

The scientific community is increasingly looking beyond amyloid and tau—the two hallmark pathologies of the disease—to explore other drivers like neuroinflammation, metabolic dysfunction, and genetic risk factors. The diverse expertise of the new SAB members positions CureAlz perfectly to lead in this new era. Their combined knowledge spans small molecules, biologics, and novel targeting mechanisms, enabling the fund to strategically place bets across a wider portfolio of next-generation approaches.

The challenge is no longer just about proving a single hypothesis but about orchestrating a multi-pronged attack on a complex, multifaceted disease. Having leaders who have successfully navigated the approval of one class of drugs provides invaluable perspective on what it will take to develop the next.

From Seed Funding to Clinical Impact

CureAlz has already proven its ability to punch above its weight class. The organization’s model of providing seed funding for proof-of-concept studies has yielded an extraordinary return on investment. Between 2018 and 2020, $47 million in grants from the fund generated an additional $350 million in follow-on funding from larger institutions like the National Institutes of Health (NIH). This 7.5x multiplier effect demonstrates its effectiveness in de-risking novel ideas and making them attractive for larger-scale investment.

With its newly fortified Scientific Advisory Board, the organization is poised to make that process even more efficient. The board's role extends beyond simply picking promising projects; it's about shaping a research portfolio that is coherent, strategic, and relentlessly focused on the finish line: a therapy that can be delivered to a patient. By integrating the pragmatic wisdom of drug development veterans, Cure Alzheimer's Fund is not just funding science; it is architecting a more direct and efficient path toward a future without Alzheimer's disease.